

Efficient Synthesis of Fused Isothiazole C-Nucleosides. 1. Synthesis of a 3- β -D-Ribofuranosylisothiazolo[4,5-*d*]pyrimidin-7(6*H*)-one Isostere of Inosine

Heinrich Wamhoff,* Rainer Berressem, and Martin Nieger

Institut für Organische Chemie und Biochemie der Universität Bonn,
Gerhard-Domagk-Strasse 1, D-53121 Bonn, FRG

Received February 18, 1993


The reaction of 2-(2,3-*O*-isopropylidene-5-*O*-trityl- β -D-ribofuranosyl)acetonitrile (6) with isopentyl nitrite/NaH and subsequent tosylation of Na-oximino nitrile 7 gave protected 2-D-ribofuranosyl-2-(tosyloximino)acetonitriles 9 α,β as novel C-nucleoside precursors. Treatment of 9 α,β with ethyl 2-mercaptoacetate under basic conditions afforded epimeric ethyl 4-aminoisothiazole-5-carboxylate C-nucleosides 10 α,β . Cyclization of 10 α,β to the desired 3-D-ribofuranosylisothiazolo[4,5-*d*]pyrimidin-7(6*H*)-ones 14 α,β was accomplished by the reaction of 10 α,β with triethyl orthoformate and subsequent aminolysis. Deprotection of 14 β and 14 α in 7% HCl/MeOH gave the title compound 3 and α -isomeric C-nucleoside 4 as monohydrochloride salt, respectively. The configuration of C-glycoside 9 α was established by X-ray crystallography.

Natural C-nucleosides,^{1,2} such as formycin (1) and formycin B (2), display significant antiviral and antitumor activities.³ In the search for new chemotherapeutic drugs in the last few years, a number of these unusual nucleosides with fused ring systems have been synthesized by replacing the natural purine bases with isosteric purine-like systems.⁴⁻⁹

We wish to report on a novel synthetic approach to purine-like C-nucleosides via C-glycosidic tosyloximino nitrile precursors. We used this approach to synthesize 3- β -D-ribofuranosylisothiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (3), an isostere of inosine, and α -isomer 4.

It has been reported in the literature that tosyloximino nitriles¹⁰ 5 are versatile compounds for heterocyclic synthesis. Their reactivity toward various nucleophiles allows nucleophilic displacement of the tosylate group and subsequent cyclization of the resulting acyclic intermediates.¹¹⁻¹⁵

Scheme I



(1) (a) Suhadolnik, R. J. *Nucleoside Antibiotics*; Wiley-Interscience: New York, 1970; pp 356-362, 367-389. (b) Suhadolnik, R. J. *Nucleosides as Biological Probes*; Wiley-Interscience: New York, 1979; pp 169-181. (c) Suhadolnik, R. J. *Prog. Nucleic Acids Res.* 1979, 22, 193.

(2) Gerzon, K.; De Long, D. C.; Cline, J. C. *Pure Appl. Chem.* 1971, 28, 489.

(3) (a) Hori, M.; Ito, E.; Takita, T.; Koyama, G.; Takeuchi, T.; Umezawa, H. *J. Antibiot.* 1964, 17A, 96. (b) Koyama, G.; Umezawa, H. *Ibid.* 1965, 18A, 175.

(4) For reviews see: (a) Hanessian, S.; Pernet, A. G. *Adv. Carbohydr. Chem. Biochem.* 1976, 33, 111-188. (b) Mizuno, Y. *The Organic Chemistry of Nucleic Acids*; Studies in Organic Chemistry 24; Kodansha Ltd.: Tokyo, 1986; p 1. (c) Farkas, I.; Kristen, H.; Peseke, K. *Wiss. Z. Wilhelm-Pieck-Universität Rostock, Naturwiss. Reihe* 1983, 32, 1. (d) Postema, M. H. D. *Tetrahedron* 1992, 48, 8545.

(5) Battacharya, B. K.; Lim, M. I.; Otter, B. A.; Klein, R. S. *Tetrahedron Lett.* 1986, 27, 815 and references cited therein.

(6) Schneller, S. W.; Thompson, R. D.; Cory, J. G.; Olsson, R. A.; De Clercq, E.; Kim, I. K.; Chiang, P. K. *J. Med. Chem.* 1984, 27, 924.

(7) Girgis, N. S.; Michael, M. A.; Smeed, D. F.; Alayhamandan, H. A.; Robins, R. K.; Cottam, H. B. *J. Med. Chem.* 1990, 33, 2750.

(8) Bhattacharya, B. K.; Otter, B. A.; Berens, R. L.; Kelin, R. S. *Nucleosides Nucleotides* 1990, 9, 1021.

(9) Sanghvi, Y. S.; Larson, S. B.; Smeed, D. F.; Revankar, G. R.; Robins, R. K. *Nucleosides Nucleotides* 1991, 10, 1417.

(10) Biehler, J. M.; Perchais, J.; Fleury, J. P. *Bull. Soc. Chim. Fr.* 1971, 7, 2711.

(11) Perchais, J.; Fleury, J. P. *Tetrahedron* 1972, 28, 2267.

(12) (a) Perchais, J.; Fleury, J. P. *Tetrahedron* 1974, 30, 999. (b) Schoeni, J. P.; Fleury, J. P. *Ibid.* 1975, 31, 671.

(13) (a) Lang, M.; Fleury, J. P. *Tetrahedron Lett.* 1974, 15, 3967. (b) Mayer, J. P.; Fleury, J. P. *Ibid.* 1980, 21, 3759. (c) Clerin, D.; Lacroix, A.; Fleury, J. P. *Ibid.* 1976, 17, 2899.

For our work on C-nucleoside synthesis, we first required a simple approach to a new tosyloximino nitrile precursor derived from 2-(2,3-*O*-isopropylidene-5-*O*-trityl- β -D-ribofuranosyl)acetonitrile (6).¹⁶ Regioselective C-nitrosation in the position α to the CN group was accomplished by treatment of 6 with isopentyl nitrite in dimethoxyethane in the presence of NaH for 12-24 h at 25 °C. This procedure afforded the sodium salt of the desired 2-(2,3-*O*-isopropylidene-5'-*O*-trityl-D-ribofuranosyl)-2-oximinoacetonitrile (7).¹⁷

The yield of 7 depended strongly on the volume of the solvent and the stoichiometry of the starting materials. Other oximino nitriles have been prepared by direct α -nitrosation of aliphatic nitriles,¹⁸ but in the case of β -C-(cyanomethyl) glycoside 6, this approach turned out to be


(14) Lang, M.; Lacroix, A.; Pont, C.; Fleury, J. P. *Helv. Chim. Acta* 1986, 69, 1025.

(15) (a) Gewald, K.; Bellmann, P.; Hänsch, H. J. *Z. Chem.* 1975, 15, 18. (b) Gewald, K.; Bellmann, P. *Liebigs Ann. Chem.* 1979, 748, 1534.

(16) Ohru, H.; Jones, G. H.; Moffat, J. G.; Maddox, M. L.; Christensen, A. T.; Byram, S. K. *J. Am. Chem. Soc.* 1975, 97, 4602.

(17) For mechanistic studies, cf.: Woodward, R. B.; Doering, W. V. E. *J. Am. Chem. Soc.* 1945, 67, 866.

Scheme II



unsuccessful. Treatment of **6** with an alkyl nitrite in the presence of strong bases, such as NaOR or KOR, resulted only in epimerization of **6** to the thermodynamically more stable α -isomer.¹⁶ Na-oximino nitrile **7**, isolable as a hygroscopic, white powder, could be used in the following tosylation step without further purification. Acidification of an aqueous solution of **7** with diluted mineralic acid afforded oximino nitrile **8** as an amorphous, hygroscopic brown precipitate that darkened in the air. Compound **8** was characterized by high-resolution mass spectrometry (HRMS).

Tosylation of **7** was achieved with TsCl. After chromatographic separation, isomeric 2-(2,3-*O*-isopropylidene-5-*O*-trityl-D-ribofuranosyl)-2-(tosyloximino)acetonitriles (**9 β** and **9 α**) were obtained in overall yields of 65% and 21%, respectively.

The C-1' stereochemistry of C-glycosides **9 β** and **9 α** was determined from their ¹H NMR spectra according to the rules given for α/β -epimeric pairs of C-nucleosides¹⁹ and 2,3-*O*-isopropylidenedated C-nucleosides,^{16,20} respectively. Thus, the 1'-H signal of the β -isomer appeared at δ 4.95

(18) (a) Metzger, H. In *Houben-Weyl, Methoden der Organischen Chemie*, Müller, E., Ed.; Thieme-Verlag: Stuttgart, 1968; Vol. X/4, p 28. (b) Unterhalt, B. In *Houben-Weyl, Methoden der Organischen Chemie*; Klamann, D., Hagemann, H., Eds.; Thieme-Verlag: Stuttgart, New York, 1990; Vol. E 14b(1), p 287. (c) Hanefeld, W. In *Houben-Weyl, Methoden der Organischen Chemie*; Klamann, D., Ed.; Thieme-Verlag: Stuttgart, New York, 1990; Vol. E 16a(2), p 950.

(19) (a) Townsend, L. B. *Synthetic Procedures in Nucleic Acid Chemistry*; Zorbach, W. W., Tipson, R. S., Eds.; Wiley-Interscience: New York, 1973; Vol. 2, p 330. (b) Lerch, U.; Burdon, M. G.; Moffat, J. G. *J. Org. Chem.* 1971, **36**, 1507. (c) De Bernardo, S.; Weigele, M. *Ibid.* 1976, **41**, 287. (d) Tam, S. Y.-K.; Klein, R. S.; Wempfen, I.; Fox, J. J. *Ibid.* 1979, **44**, 4547. (e) Chu, C. K.; El-Kabbani, F. M.; Thompson, B. B. *Nucleosides Nucleotides* 1984, **3**, 1.

(20) (a) Imbach, J.-L.; Kam, B. L. *J. Carbohydr. Nucleosides, Nucleotides* 1974, **1**, 271. (b) Tam, S. Y.-K.; Klein, R. S.; de las Heras, F. G.; Fox, J. J. *J. Org. Chem.* 1979, **44**, 4854. (c) Sokolova, T. N.; Yartseva, I. V.; Preobrazhenskaya, M. N. *Carbohydr. Res.* 1981, **93**, 19.




Figure 1. Perspective view and atom labeling of the crystal structure of 2-(2',3'-*O*-isopropylidene-5'-*O*-trityl- α -D-ribofuranosyl)-2-(tosyloximino)-acetonitrile (**11**) (50% probability thermal ellipsoids).

ppm²⁰ at higher field than that of **9 α** (δ 5.42). Furthermore, **9 β** exhibited a definitively larger difference ($\Delta\delta$) between the Me shifts of the isopropylidene groups^{16,20} (22.5 Hz for **9 β** vs 16.2 Hz for **9 α**).

The assignment of the stereochemistry of the C=N bond of **9** was made arbitrarily. For the cyclization reaction described below, the stereochemistry seemed of minor interest because of the small rotational barrier of the C=N-double bond.^{15b} The X-ray analysis of C-glycoside **9 α** revealed, however, that at least in the solid state the thermodynamically more stable *E*-configuration is preferred.

In contrast to tosyloximino nitriles **5** the C-glycosides **9 β** and **9 α** possess only one electron-withdrawing group at the oxime C-atom. The other group is replaced by the sterically-hindered sugar moiety. Because of the positive polarization of the oxime N-atom, its reactivity toward nucleophiles is strongly decreased. As a consequence, when **9 β** and **9 α** were treated with malonodinitrile and derivatives in the presence of a base, either no reaction was observed or an undesired nucleophilic attack on the sulfoxyl S-atom took place, yielding oximino nitrile **8**.


However, treating a mixture of **9 β** and **9 α** (3:1) with ethyl 2-mercaptoacetate gave, after 24 h at 25 °C, a mixture of the expected ethyl 4-amino-3-D-ribofuranosylisothiazole-5-carboxylates **10 β** and **10 α** . Chromatographic separation afforded the two isomers in a ratio of 2:5. Thus, the formation of the thermodynamically more stable α -isomer seems to be favored.

The epimerization observed at C-1' can be explained in terms of common acyclic intermediate **A**. Expulsion of the tosylate group from **A** leads to unisolable epimeric [(carbethoxymethyl)thio]imino nitriles **11 β** and **11 α** , which, in the presence of triethylamine, cyclize spontaneously to give **10 β** and **10 α** .

The configurations at C-1' of **10 α** and **10 β** were again determined by comparison of ¹H NMR data.^{16,19,20} The 1'-H signal of **10 β** appeared at higher field (δ 4.95) compared to that of **10 α** (δ 5.43). The larger difference ($\Delta\delta$) between the Me shifts of the isopropylidene groups (17.1 Hz for **10 α** vs 19.8 Hz for **10 β**) provided further evidence for the β -configuration of **10 β** .

A small amount (3%) of altronic acid derivative **12** was isolated as a byproduct; it is obviously formed by nucleo-

Scheme III




philic attack of EtOH at the oxime C-atom¹² of 9 α and subsequent hydrolysis of the resulting ethyl imidocarboxylate. This reaction is favored in the case of 9 α because of the stronger positive polarization of C-2, as indicated by the ¹³C NMR shift of C-2 (δ 147.31 for 9 α vs δ 140.26 for 9 β). The α -configuration of 12 was confirmed by the ¹³C NMR signals of the isopropylidene methyl groups found at 25.13 and 26.12 ppm, in excellent agreement with literature values for 2,3-*O*-isopropylidene- α -D-ribofuranose derivatives (24.9 ± 0.3 and 26.3 ± 0.2 ppm).^{16,21}

Isothiazole enamino esters 10 α,β are suitable precursors²² for the synthesis of purine-like isothiazolo[4,5-*d*]pyrimidine C-nucleosides. Treatment of 10 β and 10 α with triethyl orthoformate at 120 °C for 16 h gave formimido derivatives 13 β and 13 α as syrupy residues, which were not isolated but were instead cyclized with EtOH/NH₃²³ to the desired fully blocked 3- β -D-ribofuranosylisothiazolo[4,5-*d*]pyrimidin-7(6*H*)-one 14 β and α -epimer 14 α in 85% and 86% yield, respectively.

All attempts to vary the reaction conditions of the cyclization of 10 α and 10 β ,²⁴ (e.g., treatment of 10 α,β with formamide²⁵ in acetic anhydride, formamidinium acetate in boiling EtOH,²⁶ or DMF-dialkyl acetal in DMF²⁷) failed.

The ¹H NMR data revealed that, upon conversion of 10 β to 14 β and of 10 α to 14 α , no epimerization occurs at C-1'. The smaller chemical shift²⁰ of the 1'-H of 14 β (δ

Scheme IV



5.32 vs δ 5.76 for 14 α) confirmed its β -configuration. In agreement with the NMR data for several other 2,3-*O*-isopropylidened C-ribofuranosylisothiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (3) in 94% yield, and α -C-nucleoside 4 was obtained as monohydrochloride salt (90% yield).

The deprotection of 14 β and 14 α in 7% methanolic HCl at 25 °C for 1 h afforded 3- β -D-ribofuranosylisothiazolo[4,5-*d*]pyrimidin-7(6*H*)-one (3) in 94% yield, and α -C-nucleoside 4 was obtained as monohydrochloride salt (90% yield).

In primary screening, 3 and 4 turned out to be inactive against rhino viruses. Detailed investigations of the biological activities of the novel isothiazolo[4,5-*d*]pyrimidine C-nucleosides are in progress, and the results will be published elsewhere.

X-ray Crystallographic Analysis. The structure of tosyloximino nitrile C-glycoside 9 α was unambiguously confirmed by X-ray crystallography. As shown in Figure 1, the ribofuranosyl ring exhibits the *O*-1-endo envelope conformation¹⁶ in which the sterically hindered 5-*O*-trityl group and the oxime C-atom are positioned in less hindered pseudoaxial orientations.²⁹

Crystal data: C₃₆H₃₄N₂O₇S, M_r = 638.7, colorless plates, crystal dimensions 0.1 × 0.4 × 0.9 mm, crystallized from CH₃OH; monoclinic, space group *C*2 (No. 5), a = 37.114(2) Å, b = 8.288(1) Å, c = 10.983(2) Å, β = 96.35(1)°, V = 3.358(1) nm³, Z = 4, d_{calc} = 1.26 g/cm³, $\lambda(\text{Mo K}\alpha)$ = 0.710 73 Å, $\mu(\text{Mo K}\alpha)$ = 0.14 mm⁻¹, $F(000)$ = 1344. A total of 5915 symmetry-independent reflections were measured on an Enraf-Nonius CAD4 diffractometer at 25 °C ($2\theta_{\text{max}}$ = 50°, scans, scan range (0.90 + 0.35 tg θ)°, 4261 reflections with $|F| > 3\sigma(F)$ used for structure solution (direct methods) and refinement (full-matrix least-squares, 415 parameters), non-hydrogen atoms refined anisotropically, H atoms localized by difference electron density determination and refined by means of a "riding" model; R = 0.044 (R_w =

(21) Secrist, J. A., III. *J. Org. Chem.* 1978, 43, 2925.

(22) Wamhoff, H. *Adv. Heterocycl. Chem.* 1985, 38, 299.

(23) Gompper, R.; Kutter, E.; Töpfl, W. *Liebigs Ann. Chem.* 1962, 659, 90.

(24) Albert, A. *Adv. Heterocycl. Chem.* 1982, 32, 2.

(25) Wamhoff, H.; Lichtenthaler, L. *Chem. Ber.* 1978, 111, 2297.

(26) Lim, M. I.; Ren, W. Y.; Otter, B. A.; Klein, R. S. *J. Org. Chem.* 1983, 48, 780 and references cited therein.

(27) Abdulla, R. F.; Brinkmeyer, R. S. *Tetrahedron* 1979, 35, 1675.

(28) (a) Cousineau, T. J.; Secrist, J. A., III. *J. Org. Chem.* 1979, 44, 4351. (b) Poonian, M. S.; Nawoswiat, E. F. *Ibid.* 1980, 45, 203. (c) Logue, M. S.; Sarangan, S. *Nucleosides Nucleotides* 1982, 1, 89.

(29) The author has deposited atomic coordinates for this structure with the Cambridge Crystallographic Data Centre. The coordinates can be obtained, on request, from the Director, Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK.

0.040, $w^{-1} = \sigma^2(F) + 0.0005F^2$), the absolute configuration was confirmed by *n*-refinement ($n = 1.2(2)$), largest peak in final difference Fourier map $0.28 \text{ e } \text{Å}^{-3}$. The structure was solved and refined with SHELXTL-Plus.

Experimental Section

Melting points are not corrected. Microanalyses were carried out by the analytical laboratory of the Institute. The yields refer to analytically pure compounds. TLC was performed with Merck silica gel plates 60 F₂₅₄ and column chromatography by standard techniques on merck silica gel 60 (70–230 mesh). Light petroleum ether (bp 40–60 °C) was used whenever this solvent was required. The following instruments were used for spectroscopic measurements: UV, Cary-17; IR, Perkin-Elmer 157-G; MS, A.E.I. (Kratos) MS-50, 70 eV; ¹H NMR and ¹³C NMR, Bruker WH-90, AC-200, and AM-400.

The NMR spectra were measured at 90, 200, and 400 MHz. TMS at 0.0 ppm was used as the internal standard for the ¹H NMR spectra, and the central line of either CDCl₃ (δ 77.0) or DMSO-*d*₆ (δ 39.5) was referenced in ¹³C NMR spectra.

2-(2,3-O-Isopropylidene-5-O-trityl-D-ribofuranosyl)-2-oximinoacetonitrile Sodium Azaenolate (7). To a mixture of 6 (10 g, 22 mmol) and isopentyl nitrite (9 mL, 66 mmol) in dry DME (50 mL) was added NaH (2.11 g, 88 mmol), and the resulting suspension was stirred at 25 °C under anhydrous conditions for 12–24 h. After the reaction was completed (monitored by TLC), the resulting light-brown reaction mixture containing 7 was used without workup for the next step: HRMS of the corresponding oximino nitrile 8 calcd for C₂₉H₂₈N₂O₄, 484.1998, found 484.1995; MS *m/z* 484 (M⁺, 1.5).

2-(2,3-O-Isopropylidene-5-O-trityl-D-ribofuranosyl)-2-(tosyloximino)acetonitriles (9 β and 9 α). After addition of dry DME (250 mL) and dropwise addition of glacial acetic acid (2.52 mL, 44 mmol) to the reaction mixture of 7 at 0 °C, a solution of tosyl chloride (9.23 g, 48.4 mmol) in dry DME (100 mL) was added over a period of 1 h. The viscous suspension obtained was stirred for an additional 15 h at 25 °C. The NaCl/NaOAc formed was filtered over Celite and washed several times with DME. The filtrate was evaporated to dryness, and the resulting syrup was chromatographed on silica gel (petroleum ether–ethyl acetate (14:5)) to give, after crystallization from MeOH, 9 β and 9 α as pale yellow solids.

β -C-Glycoside 9 β (more polar): 9.1 g (65%); mp 78–82 °C; UV (CH₂Cl₂) λ_{max} (log ϵ) 206 (4.19), 219 nm (4.38); IR (KBr) 2215 (C=N), 1595 (C=C), 1390, 1195 cm⁻¹ (S=O); ¹H NMR (90 MHz, CDCl₃) δ 4.95 (d, 1 H, $J = 4.0$ Hz, 1'-H), 4.93 (t, 1 H, $J = 6.2$ Hz, 2'-H), 4.67 (m, 1 H, 3'-H), 4.38 (t, 1 H, $J = 3.6$ Hz, 4'-H), 3.37 (dd, 1 H, $J = 10.9$, 3.4 Hz, 5'a-H), 3.08 (dd, 1 H, $J = 10.9$, 3.6 Hz, 5'b-H), 2.42 (s, 3 H, CH₃), 1.47 (s, 3 H, CH₃), 1.22 (s, 3 H, CH₃), 7.93–7.11 (m, 19 H, trityl and AA'BB', tosyl); ¹³C NMR (200 MHz, CDCl₃) δ 146.42, 130.82, 129.96, 129.16, 21.73 (tosyl), 143.15, 128.39, 127.98, 127.29, 87.52 (trityl), 140.26 (C-2), 107.33 (C-1), 85.06 (C-1'), 83.10 (C-4'), 82.97 (C-2'), 80.10 (C-3'), 64.80 (C-5'), 114.16, 24.78, 24.15 (C(CH₃)₂); MS *m/z* 638 (M⁺, 0.1). Anal. Calcd for C₃₆H₃₄N₂O₇S·CH₃OH: C, 66.25; H, 5.71; N, 4.18. Found: C, 66.46; H, 5.70; N, 4.06.

α -Isomer 9 α (less polar): 2.9 g (21%); mp 158 °C; UV (CH₂Cl₂) λ_{max} (log ϵ) 225 nm (4.34); IR (KBr) 2220 (C=N), 1590 (C=C), 1390, 1195 cm⁻¹ (S=O); ¹H NMR (90 MHz, CDCl₃) δ 5.42 (d, 1 H, $J = 4.6$ Hz, 1'-H), 5.08 (t, 1 H, $J = 5.4$ Hz, 2'-H), 4.54 (d, 1 H, $J = 6.4$ Hz, 3'-H), 4.30 (t, 1 H, $J = 3.0$ Hz, 4'-H), 3.44 (dd, 1 H, $J = 10.6$, 2.4 Hz, 5'a-H), 2.98 (dd, 1 H, $J = 10.6$, 2.2 Hz, 5'b-H), 2.34 (s, 3 H, CH₃), 1.31 (s, 3 H, CH₃), 1.13 (s, 3 H, CH₃), 7.87–7.13 (m, 19 H, trityl and AA'BB', tosyl); ¹³C NMR (200 MHz, CDCl₃) δ 146.46, 130.93, 130.05, 129.32, 21.89 (tosyl), 143.19, 128.51, 128.24, 127.49, 88.04 (trityl), 147.31 (C-2), 110.74 (C-1), 84.59 (C-1'), 83.03 (C-4'), 81.89 (C-3'), 78.86 (C-2'), 65.52 (C-5'), 113.47, 25.59, 24.43 (C(CH₃)₂); MS *m/z* 638 (M⁺, 0.4). Anal. Calcd for C₃₆H₃₄N₂O₇S: C, 67.70; H, 5.37; N, 4.39. Found: C, 67.72; H, 5.57; N, 4.60.

Ethyl 4-Amino-3-(2,3-O-isopropylidene-5-O-trityl-D-ribofuranosyl)isothiazole-5-carboxylates (10 β and 10 α). Isomeric tosyloximino nitriles 9 β and 9 α (10 g, 15.7 mmol, 3:1), ethyl 2-mercaptoacetate (2.1 mL, 18.8 mmol), and triethylamine (3.3 mL, 23.6 mmol) were dissolved in dry EtOH (200 mL), and

the reaction mixture was stirred at 25 °C for 24 h. After evaporation, the residue obtained was chromatographed (cyclohexane–ethyl acetate (7:1)) to afford epimeric isothiazoles 10 β and 10 α as white solids after crystallization from EtOH and byproduct 12 as colorless needles from MeOH.

β -Nucleoside 10 β (less polar): 1.8 g (20%); mp 79–82 °C; UV (CH₂Cl₂) λ_{max} (log ϵ) 336 (3.90), 205 nm (4.35); IR (KBr) 3460, 3330 (NH), 1690 (C=O), 1595 cm⁻¹ (C=C); ¹H NMR (90 MHz, CDCl₃) δ 4.95 (d, 1 H, $J = 4.4$ Hz, 1'-H), 5.28 (dd, 1 H, $J = 6.8$, 4.8 Hz, 2'-H), 4.64 (dd, 1 H, $J = 6.6$, 3.0 Hz, 3'-H), 4.28 (m, 1 H, 4'-H), 3.04 (m, 2 H, 5'a,b-H), 4.22 (q, 2 H, $J = 7.4$ Hz, CH₂), 1.23 (t, 3 H, $J = 6.8$ Hz, CH₃), 1.48 (s, 3 H, CH₃), 1.26 (s, 3 H, CH₃), 7.38–7.04 (m, 15 H, trityl), 5.59 (br s, 2 H, NH₂); ¹³C NMR (200 MHz, CDCl₃) δ 162.43 (C=O), 157.01 (C-4), 147.51 (C-3), 122.39 (C-5), 143.42, 128.60, 127.90, 127.19, 86.97 (trityl), 84.60 (C-1'), 84.20 (C-4'), 83.19 (C-2'), 81.85 (C-3'), 63.41 (C-5'), 114.32, 27.34, 25.43 (C(CH₃)₂), 60.84, 14.38 (OCH₂CH₃); MS *m/z* 586 (M⁺, 0.4). Anal. Calcd for C₃₃H₃₄N₂O₆S: C, 67.56; H, 5.84; N, 4.77. Found: C, 67.30; H, 5.86; N, 5.08.

α -Isomer 10 α (more polar): 4.8 g (52%); mp 80–85 °C; UV (CH₂Cl₂) λ_{max} (log ϵ) 335 (3.97), 205 nm (4.47); IR (KBr) 3490, 3370 (NH), 1685 (C=O), 1590 cm⁻¹ (C=C); ¹H NMR (90 MHz, CDCl₃) δ 5.43 (d, 1 H, $J = 4.8$ Hz, 1'-H), 4.99 (dd, 1 H, $J = 5.6$, 4.4 Hz, 2'-H), 4.67 (d, 1 H, $J = 6.2$ Hz, 3'-H), 4.35 (t, 1 H, $J = 2.5$ Hz, 4'-H), 3.22 (m, 2 H, 5'a,b-H), 4.25 (q, 2 H, $J = 7.2$ Hz, CH₂), 1.27 (t, 3 H, $J = 6.6$ Hz, CH₃), 1.39 (s, 3 H, CH₃), 1.20 (s, 3 H, CH₃), 7.49–7.11 (m, 15 H, trityl), 5.85 (br s, 2 H, NH₂); ¹³C NMR (90 MHz, CDCl₃) δ 162.75 (C=O), 154.91 (C-4), 149.31 (C-3), 121.19 (C-5), 143.49, 128.69, 128.11, 127.34, 87.55 (trityl), 84.42 (C-1'), 83.83 (C-3'), 83.41 (C-4'), 82.60 (C-2'), 64.15 (C-5'), 112.83, 26.02, 24.08 (C(CH₃)₂), 60.72, 14.44 (OCH₂CH₃); MS *m/z* 586 (M⁺, 1.9). Anal. Calcd for C₃₃H₃₄N₂O₆S: C, 67.56; H, 5.84; N, 4.77. Found: C, 67.03; H, 5.63; N, 4.40.

Ethyl 2,5-anhydro-3,4-O-isopropylidene-6-O-trityl-D-altronate (12): 0.4 g (3%); mp 153 °C; UV (CH₂Cl₂) λ_{max} (log ϵ) 217 nm (4.18); IR (KBr) 1750 (C=O), 1595 cm⁻¹ (C=C); ¹H NMR (200 MHz, CDCl₃) δ 4.94 (d, 1 H, $J = 5.1$ Hz, 1'-H), 5.14 (t, 1 H, $J = 5.5$ Hz, 2'-H), 4.70 (dd, 1 H, $J = 6.0$, 1.2 Hz, 3'-H), 4.42 (t, 1 H, $J = 3.4$ Hz, 4'-H), 3.43 (dd, 1 H, $J = 10.1$, 3.4 Hz, 5'a-H), 3.10 (dd, 1 H, $J = 10.1$, 3.1 Hz, 5'b-H), 4.31 (m, 2 H, $J = 3.6$ Hz, CH₂), 1.33 (t, 3 H, $J = 7.2$ Hz, CH₃), 1.45 (s, 3 H, CH₃), 1.30 (s, 3 H, CH₃), 7.42–7.18 (m, 15 H, trityl); ¹³C NMR (200 MHz, CDCl₃) δ 168.45 (C=O), 143.40, 128.55, 127.98, 127.23, 87.45 (trityl), 84.17 (C-1'), 82.75 (C-4'), 82.50 (C-2'), 82.33 (C-3'), 65.04 (C-5'), 113.07, 26.12, 25.13 (C(CH₃)₂), 61.14, 14.31 (OCH₂CH₃); HRMS *m/z* calcd 488.2199, found 488.2203; MS *m/z* 488 (M⁺, 0.7). Anal. Calcd for C₃₀H₃₂O₆: C, 73.77; H, 6.56. Found: C, 73.85; H, 6.60.

3-(2,3-O-Isopropylidene-5-O-trityl-D-ribofuranosyl)isothiazolo[4,5-*d*]pyrimidin-7(6*H*)-ones (14 β and 14 α). A solution of isothiazole C-nucleoside 10 β or 10 α in dry triethyl orthoformate (20–30 mL) was heated with stirring at 120 °C for 16 h. After evaporation of the reaction mixture, the resulting residue was dissolved in dry EtOH (30–40 mL), and a stream of dry ammonia gas was passed into the solution for 24 h at 25 °C. Evaporation of the reaction mixture and crystallization of the residue from MeOH gave fully blocked C-nucleosides 14 β and 14 α , respectively, as white solids.

β -Nucleoside 14 β (1.64 g, 85%) was obtained from 10 β (2 g, 3.41 mmol) as colorless needles after recrystallization from MeOH: mp 196 °C; UV (CH₂Cl₂) λ_{max} (log ϵ) 304 (3.99), 230 (4.34), 217 nm (4.46); IR (KBr) 3180 (NH), 1690 (C=O), 1590, 1580 cm⁻¹ (C=C, C=N); ¹H NMR (90 MHz, DMSO-*d*₆) δ 5.32 (d, 1 H, $J = 4.0$ Hz, 1'-H), 5.26 (m, 1 H, 2'-H), 4.75 (dd, 1 H, $J = 5.6$, 3.0 Hz, 3'-H), 4.27 (m, 1 H, 4'-H), 3.00 (m, 2 H, 5'a,b-H), 1.50 (s, 3 H, CH₃), 1.27 (s, 3 H, CH₃), 8.22 (s, 1 H, 5-H), 7.44–7.11 (m, 15 H, trityl), 3.15 (br s, 1 H, OH); ¹³C NMR (200 MHz, DMSO-*d*₆) δ 164.09 (C=O), 155.76 (C-3a), 150.70 (C-3), 148.04 (C-5), 141.60 (C-7a), 143.53, 128.21, 127.80, 126.98, 86.00 (trityl), 84.62 (C-1'), 83.12 (C-4'), 82.51 (C-2'), 80.61 (C-3'), 64.02 (C-5'), 113.11, 27.20, 25.30 (C(CH₃)₂); MS *m/z* 567 (M⁺-H, 6.0). Anal. Calcd for C₃₂H₂₈N₂O₆S: C, 67.71; H, 5.15; N, 7.40. Found: C, 67.32; H, 5.25; N, 7.28.

10 α (1.5 g, 2.65 mmol) gave 1.25 g (86%) of α -isomer 14 α as colorless plates after recrystallization from MeOH: mp 253 °C; UV (CH₂Cl₂) λ_{max} (log ϵ) 303 (3.81), 232 (4.08), 210 nm (4.50); IR (KBr) 3190 (NH), 1690 (C=O), 1580 cm⁻¹ (C=C, C=N); ¹H

NMR (400 MHz, DMSO- d_6) δ 5.76 (d, 1 H, $J = 4.6$ Hz, 1'-H), 5.29 (t, 1 H, $J = 6.2$ Hz, 2'-H), 4.73 (d, 1 H, $J = 6.9$ Hz, 3'-H), 4.38 (t, 1 H, $J = 4.6$ Hz, 4'-H), 3.28 (dd, 1 H, $J = 10.0, 3.8$ Hz, 5'a-H), 3.19 (dd, 1 H, $J = 10.0, 4.6$ Hz, 5'b-H), 8.32 (s, 1 H, 5-H), 1.17 (s, 3 H, CH₃), 1.15 (s, 3 H, CH₃), 7.46–7.24 (m, 15 H, trityl), 3.35 (br s, 1 H, OH); ¹³C NMR (400 MHz, DMSO- d_6) δ 162.72 (C=O), 155.87 (C-3a), 150.13 (C-3), 148.19 (C-5), 140.17 (C-7a), 143.43, 128.25, 128.05, 127.17, 86.76 (trityl), 82.70 (C-1'), 82.42 (C-4'), 81.94 (C-3'), 81.00 (C-2'), 64.20 (C-5'), 112.14, 25.85, 24.97 (C(CH₃)₂); MS m/z 567 (M⁺, 0.2). Anal. Calcd for C₃₂H₂₉N₃O₅S: C, 67.71; H, 5.15; N, 7.40. Found: C, 67.45; H, 5.28; N, 7.39.

3-D-Ribofuranosylisothiazolo[4,5-*d*]pyrimidin-7(6*H*)-ones 3 and 4. Protected C-nucleosides 14 β and 14 α were dissolved separately in 7% methanolic HCl (15–20 mL) and stirred for 1 h at 25 °C. After evaporation of the solvent, the residues were crystallized from Et₂O and filtered, and the white precipitates obtained were washed several times with Et₂O.

Recrystallization of the β -C-nucleoside 3 from 2-propanol afforded 0.16 g (94%) from 0.34 g (0.6 mmol) of 14 β : mp 192 °C; UV (pH = 7) λ_{\max} (log ϵ) 303 (4.06), 238 (4.13), 205 nm (4.24); IR (KBr) 3400–3100 (OH, NH), 1705 (C=O), 1590 cm⁻¹ (C=N); ¹H NMR (200 MHz, DMSO- d_6) δ 5.10 (d, 1 H, $J = 6.7$ Hz, 1'-H), 4.48 (q, 1 H, $J = 5.5$ Hz, 2'-H), 4.06 (q, 1 H, $J = 5.0$ Hz, 3'-H), 3.90 (q, 1 H, $J = 4.2$ Hz, 4'-H), 3.53 (m, 2 H, 5'a,b-H), 8.39 (s, 1 H, 5-H), 5.16 (d, 1 H, $J = 6.3$ Hz, 2'-OH), 5.02 (d, 1 H, $J = 5.1$ Hz, 3'-OH), 4.93 (m, 1 H, 5'-OH) 12.96 (br s, 1 H, NH); ¹³C NMR (200

MHz, DMSO- d_6) δ 165.43 (C=O), 155.88 (C-3a), 150.70 (C-3), 148.12 (C-5), 141.68 (C-7a), 85.84 (C-1'), 79.70 (C-4'), 74.16 (C-2'), 71.89 (C-3'), 62.38 (C-5'); MS m/z 285 (M⁺, 14.0). Anal. Calcd for C₁₀H₁₁N₃O₅S: C, 42.06; H, 3.86; N, 14.72. Found: C, 41.73; H, 3.64; N, 14.34.

14 α (0.45 g, 0.8 mmol) gave 0.23 g (90%) of α -isomer 4 after recrystallization from MeOH, as a crystalline monohydrochloride salt: mp 253 °C; UV (pH = 7) λ_{\max} (log ϵ) 303 (4.21), 237 (4.29), 203 nm (4.41); IR (KBr) 3450–3100 (OH, NH), 1670 (C=O), 1580 cm⁻¹ (C=N); ¹H NMR (200 MHz, DMSO- d_6) δ 5.47 (d, 1 H, $J = 4.2$ Hz, 1'-H), 4.45 (t, 1 H, $J = 4.3$ Hz, 2'-H), 4.12 (dd, 1 H, $J = 8.1, 4.7$ Hz, 3'-H), 3.96 (m, 1 H, 4'-H), 3.68 (dd, 1 H, $J = 11.4, 3.5$ Hz, 5'a-H), 3.48 (dd, 1 H, $J = 11.7, 4.4$ Hz, 5'b-H), 8.26 (s, 1 H, 5-H), 5.55 (br s, 1 H, OH); ¹³C NMR (200 MHz, DMSO- d_6) δ 164.94 (C=O), 156.00 (C-3a), 150.17 (C-3), 147.91 (C-5), 140.33 (C-7a), 82.60 (C-1'), 80.14 (C-4'), 72.69 (C-3'), 72.09 (C-2'), 61.49 (C-5'); MS m/z 285 (M⁺, 5.0). Anal. Calcd for C₁₀H₁₂N₃O₅S·HCl·0.5CH₃OH: C, 37.33; H, 4.44; N, 12.44. Found: C, 37.76; H, 4.51; N, 12.22.

Acknowledgment. We thank the Fonds der Chemischen Industrie and the BAYER AG, Leverkusen, for their support of this research and Dr. G. Eckhardt, Dr. S. Schuth, and Mr. C. Schmidt for their spectroscopic measurements and helpful discussions.